- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06153940
Everglade Stem, World Cup and World Liner Post Market Clinical Follow-up
Study Overview
Detailed Description
The Objective of this Post market Clinical Follow up (PMCF) study is to collect data confirming safety, performance and clinical benefits of the Everglade Stem, World Acetabular Cup and World Liner when used for a primary total hip arthroplasty at 2 years follow-up.
This prospective follow-up series is necessary to gather data for the Everglade Stem, World Acetabular Cup and World Liner as they are recently launched to the market.
The data concerning the performance and safety of the devices are gathered in various time frames starting with pre-operative status and then includes operative, at discharge, i year post-operative and 2 year post-operative evaluations.
The revision rate of the components will be monitored as the primary objective, along with pre- and post-operative measurement of the Oxford Hip Score(OHS) patient-reported outcome measure(PROM) to quantify patient satisfaction and radiographic analysis to monitor the bony response to the implants and quantify the effectiveness of the cementless fixation.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Declan Brazil, PhD
- Phone Number: +61 02 9428 5181
- Email: declan@signatureortho.com.au
Study Contact Backup
- Name: Satish A Shejale, M.S. Orthopaedics
- Phone Number: +61 02 9428 5181
- Email: satish.shejale@signatureortho.com.au
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Laura Stiegel
- Email: stiegel@ccf.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patient requires unilateral primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, dysplasia/DDH)
- patient must be a candidate for use of the products studied, as determined jointly by the surgeon and patient
- male and non-pregnant female patients aged 18-75
- patients who understand the conditions of the clinical evaluation and are willing to participate for the length of the prescribed follow-up
Exclusion Criteria:
- patient has active infection or sepsis(treated or untreated) enough to compromise implant stability or postoperative recovery
- patient is a female of child-bearing age and not taking and not taking contraceptive pills
- patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia)
- patient has a known or suspected metal sensitivity
- patient is immuno-suppressed with disease such as AIDS or is receiving high dose of cortico-steroids.
- patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the clinical evaluation including mental illness, mental retardation or drug abuse
- patient is severely overweight with a BMI>40.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Everglade Stem, World Cup and World Liner Survival Rate
Time Frame: upto 2 years
|
The implant survival rate based on removal of the device for any reason as determined following the Kaplan-Meier method
|
upto 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oxford Hip Score (OHS)
Time Frame: up to 2 years
|
The OHS is a patient reported outcome measure (PROM) used to quantify patient satisfaction with the treatment.
The OHS consists of 12 questions scored 1 to 5 by the patient.
|
up to 2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Radiographic Analysis
Time Frame: up to 2 years.
|
Post-operative radiographs of the implant are analysed to identify locations and sizes of radiolucency, indicative of poor fixation.
The size, location and progression of radiolucencies is monitored.
Smaller, non-progressive radiolucencies are preferred.
|
up to 2 years.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nicolas Piuzzi, MD, The Cleveland Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 111-450-100
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hip Disease
-
FH ORTHORecruitingHip Fractures | Hip DiseaseFrance
-
Zhenjiang First People's HospitalCompletedHip Fractures | Hip DiseaseChina
-
Signature OrthopaedicsThe Cleveland ClinicRecruiting
-
OSF Healthcare SystemUniversity of Illinois College of Medicine at PeoriaCompletedHip Disease
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Istituto Ortopedico GaleazziCompleted
-
Assiut UniversityNot yet recruiting
-
Hospital for Special Surgery, New YorkCompletedHip DiseaseUnited States
-
University of Colorado, DenverCompletedHip DiseaseUnited States
Clinical Trials on Treatment
-
PfizerCompleted
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
JW PharmaceuticalCompletedHealthyKorea, Republic of
-
PfizerCompleted
-
AstraZenecaParexelCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingIntra-articular Fracture of the Mandibular CondyleFrance
-
PfizerCompletedHealthy VolunteersUnited States
-
New Mexico VA Healthcare SystemCompletedPost Traumatic Stress DisorderUnited States